Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 3, March, p. 429–436

doi: 10.17219/acem/67968

Publication type: review article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Plasma lipid transfer proteins: The role of PLTP and CETP in atherogenesis

Zbyszko Chowaniec1,A,B,C,D, Anna Skoczyńska1,A,C,E,F

1 Department and Clinic of Internal and Occupational Diseases and Hypertension, Wroclaw Medical University, Poland


Cardiovascular diseases are still the main cause of death in Poland and throughout the world. Independent risk factors of cardiovascular disease, in addition to elevated LDL cholesterol, are both low HDL levels and high levels of non-HDL cholesterol. Plasma phospholipid-transfer protein (PLTP) and cholesteryl ester transfer protein (CETP) both play a major role in the metabolism of those lipoproteins. A lack of these proteins increases HDL and lowers LDL levels. In the light of current knowledge, it seems reasonable to search for compounds that may decrease the activity of CETP, and thus reduce the incidence of cardiovascular disease. Whereas on the one hand there are reports about the adverse effect of torcetrapib and the lack of therapeutic effects of dalcetrapib, on the other hand the question arises whether the CETP inhibitors that are currently in clinical trials will rise to the challenges before them. Currently, it is known that the activity of PLTP, while affecting the metabolism of lipoproteins, especially HDL, plays a major role in atherogenesis. Still, there are some contradictions and controversies about the effect of PLTP on reverse cholesterol transport (RCT). There are a number of studies about the role that PLTP plays in the pathogenesis of various diseases. Further studies are needed to clearly determine the impact of PLTP activity on the formation and development of pathological processes in the cardiovascular system.

Key words

CETP, atherogensis, PLTP

References (54)

  1. Day JR, Albers JJ, Lofton-Day CE, et al. Complete cDNA encoding human phospholipid transfer protein from human endothelial cells. Biol Chem. 1994;269:9388–9391.
  2. Huuskonen J, Olkonnen VM, Jauhiainien M, Ehnholm C. The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis. 2001;155:269–281.
  3. Masson D, Jiang XC, Lagrost L, Tall AR. The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J Lipid Res. 2009;50:201–206. doi: 10.1194/jlr.R800061-JLR200
  4. Ji A, Wroblewski JM, Webb NR, van der Westhuyzen DR. Impact of phospholipid transfer protein on nascent high-density lipoprotein formation and remodeling. Arterioscler Thromb Vasc Biol. 2014;34:1910–1916.
  5. Quintão EC, Cazita PM. Lipid transfer proteins: Past, present and perspectives. Atherosclerosis. 2010;209:1–9.
  6. Jiang XC1, Jin W, Hussain MM. The impact of phospholipid transfer protein (PLTP) on lipoprotein metabolism. Nutr Metab. 2012;9(1):75.
  7. Di Bartolo B, Takata K, Duong M, Nicholls SJ. CETP inhibition in CVD prevention: An actual appraisal. Curr Cardiol Rep. 2016;18(5):43.
  8. Bruce C, Beamer LJ, Tall AR. The implications of the structure of the bactericidal/permeability-increasing protein on the lipid-transfer function of the cholesteryl ester transfer protein. Curr Opin Struct Biol. 1998;8:426–434.
  9. Yamashita S, Hirano K, Sakai N, Matsuzaw Y. Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer pro- tein. Biochim Biophys Acta. 2000;1529:257–275.
  10. Tu AY, Deeb SS, Iwasaki L, Day JR, Albers JJ. Organization of human phospholipid transfer protein gene. Biochem Biophys Res Comm.1995;207:552–558.
  11. Albers JJ, Vuletic S, and Cheung MC. Role of plasma phospholipid transfer protein in lipid and lipoprotein letabolism. Biochim Biophys Acta. 2012;1821:345–357.
  12. Beamer LJ, Carrol SF, Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science. 1997;276:1861–1864.
  13. Qiu XY, Mistry A, Ammirati MJ. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol. 2007;14:106–113.
  14. Bouly M, Masson D, Gross B, et al. Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. J Biol Chem. 2001;276:25841–25847.
  15. Riemens SC, van Tol A, Sluiter WJ, Dullaart RP. Plasma phospholipid transfer protein activity is lowered by 24-h insulin and acipimox administration: Blunted response to insulin in type 2 diabetic patients. Diabetes. 1999;48:1631–1637.
  16. Lewis GF. Are the lipid-modifying effects of fibrates mediated by alterations in plasma lipid transfer activity? Clin Sci. 2006;111:185–187.
  17. Levels JH, Pajkrt D, Schultz M, et al. Alterations in lipoprotein homeostasis during human experimental endotoxemia and clinical sepsis. Biochim Biophys Acta. 2007;1771:1429–1438.
  18. Tzotzas T, Desrumaux C, Lagrost L. Plasma phospholipid transfer protein (PLTP): Review of an emerging cardiometabolic risk factor. Obes Rev. 2009;10:403–411.
  19. Desrumaux C, Athias A, Bessede G, et al. Mass concentration of plas- ma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA. Arterioscler Thromb Vasc Biol. 1999;19:266–275.
  20. Oomen PH, van Tol A, Hattori H, Smit AJ, Scheek LM, Dullaart RP. Human plasma phospholipid transfer protein activity is decreased by acute hyperglycaemia: Studies without and with hyperinsulinaemia in type 1 diabetes mellitus. Diabet Med. 2005;22:768–774.
  21. Oka T, Kujiraoka T, Ito M, et al. Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. J Lipid Res. 2000;41:1651–1657.
  22. Oka T, Yamashita S, Kujiraoka T, et al. Distribution of human plasma PLTP mass and activity in hypo- and hyperalphalipoproteinemia. J Lipid Res. 2002;43:1236–1243.
  23. Drayna, D, Jarrnagin AS, McLean J, et al. Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature. 1987;327:632–634.
  24. Son YS, Zilversmit DB. Increased lipid transfer activities in hyperlip- idemic rabbit plasma. Arteriosclerosis. 1986;6:345–351.
  25. Dedecjus M , Masson D, Gautier T, et al. Low cholesteryl ester transfer protein (CE TP) concentration but normal CE TP ac tivit y in serum from patients with shor t-term hypothyroidism. Lack of relationship to lip oprotein abnormalities . Clin Endo crinol. 2003;58:581–588.
  26. Albers JJ, Wolfbauer G, Cheung MC, et al. Functional expression of human and mouse plasma phospholipid transfer protein: Ef fect of recombinant and plasma PLTP on HDL subspecies. Biochim Bio- phys Acta. 1995;1258:27–34.
  27. Settasatian N, Duong M, Curtiss LK, et al. The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein. J Biol Chem. 2001;276: 26898–26905.
  28. Zannis VI. et al. HDL Biogenesis, Remodeling, and Catabolism. In: von Eckardstein A, Kardassis D, eds. High Density Lipoproteins. Handbook of Experimental Pharmacology, vol. 224. Springer, Cham; 2015.
  29. Lee-Rueckert M, Vikstedt R, Metso J, Ehnholm C, Kovanen PT, Jauhiainen M. Absence of endogenous phospholipid transfer protein impairs ABCA1-dependent efflux of cholesterol from macrophage foam cells. J Lipid Res. 2006;47:1725–1732.
  30. Moerland M, Samyn H, van Gent T, et al. Acute elevation of plasma PLTP activity strongly increases pre-existing atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28:1277–1282.
  31. Moerland M, Samyn H, van Gent T, et al. Atherogenic, enlarged, and dysfunctional HDL in human PLTP/apoA-I double transgenic mice. J Lipid Res. 2007;48:2622–2631.
  32. Cheung MC, Wolfbauer G, Deguchi H, Fernandez JA, Grif fin JH, Albers JJ. Human plasma phospholipid transfer protein specific activity is correlated with HDL size: Implications for lipoprotein physiology. Biochim Biophys Acta. 2009;1791:206–211.
  33. Barter PJ, Hopkins GJ, Calvert GD. Transfers and exchanges of esterified cholesterol between plasma lipoproteins. Biochem J. 1982;208:1–7.
  34. Barter PJ, Brewer Jr HB, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein. A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:160–167.
  35. Guerin M, Lassel TS, Le Gof f W, Farnier M, Chapman MJ. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol. 2000;20:189–197.
  36. Zhang L, Yan F, Zhang S, et al. Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein. Nat Chem Bio. 2012;8:342–349.
  37. Zhang M, Charles R, Tong H, et al. HDL surface lipids mediate CETP binding as revealed by electron microscopy and molecular dynamics simulation. Sci Rep. 2015;5:1-8. doi:10.1038/srep08741
  38. Tabas I. Cholesterol and phospholipid metabolism in macrophages. Biochim Biophys Acta. 2000;1529:164–174.
  39. Valenta DT, Bulgrien JJ, Bonnet DJ, Curtiss LK. Macrophage PLTP is atheroprotective in LDLr-deficient mice with systemic PLTP defi- ciency. J Lipid Res. 2008;49:24–32.
  40. Miller SI, Ernst RK, Bader MW. LPS, TLR4 and infectious disease diversity. Nat Rev Microbiol. 2005;3:36–46.
  41. Gautier T, Lagrost L. Plasma PLTP (phospholipid-transfer protein): an emerging role in oka’reverse lipopolysaccharide transport’ and innate immunity. Biochem Soc Trans. 2011;39: 984–988.
  42. Hailman E, Albers JJ, Wolfbauer G, Tu AY, Wright SD. Neutralization and transfer of lipopolysaccharide by phospholipid transfer protein. J Biol Chem. 1996;271:12172–12178.
  43. Ferkingstad E, Frigessi A, Lyng H. Indirect genomic effects on survival from gene expression data. Genome Biol. 2008;9:R58–R72.
  44. Jiang XC, Masucci-Magoulas L, Mar J, et al. Down-regulation of mRNA for the low density lipoprotein receptor in transgenic mice containing the gene for human cholesteryl ester transfer protein: mechanism to explain accumulation of lipoprotein B particles. J Biol Chem.1993;268:27406–27412.
  45. Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature. 1993;364:73–75.
  46. Kako Y, Massé M, Huang LS, Tall AR, Goldberg IJ, et al. Lipoprotein lipase deficiency and CETP in streptozotocin-treated apoB-expressing mice. J Lipid Res. 2002;43:872–877.
  47. Sugano M, Makino N, Sawada S, et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem. 1998;273:5033–5036.
  48. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000;406:203–207.
  49. Aghebati T, Badiee A, Mohammadpour AH, et al. Anti-atherosclerosis effect of different doses of CETP vaccine in rabbit model of atherosclerosis. Biomed Pharmacother. 2016; 81,468–473.
  50. Thompson A, Di Angelantonio E, Sarwar N. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA.2008;299:2777–2788.
  51. Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res. 2006;47:537–552.
  52. Stroes ES, Kastelein JJ, Benardeau A, et al. Dalcetrapib: No off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats. Br J Pharmacol. 2009;158:1763–1770.
  53. Durrington PN. Cholesteryl ester transfer protein (CETP) inhibitors. Br J Cardiol. 2012;19:126–133.
  54. Filippatos TD, Kei A, Elisaf MS. Anacetrapib, a new CETP inhibitor: The new tool for the management of dyslipidemias? Diseases. 2017;5:21. doi:10.3390/diseases5040021